Induced Psychosis in a Patient Treated for Pulmonary Tuberculosis

Isoniazid is a cornerstone drug in tuberculosis treatment due to its high efficacy but is associated with rare neuropsychiatric side effects, including psychosis. The exact mechanisms are not fully understood but may involve inhibition of monoamine oxidase, oxidative stress affecting NMDA receptors, and disruption of vitamin B6 metabolism, leading to neurotransmitter imbalances. Psychosis onset varies from days to weeks after treatment initiation. We report a case of a 40-year-old patient who developed psychotic symptoms eight weeks after starting isoniazid-based treatment for pulmonary tuberculosis.